Video summary

ALD6.0 24Aug25 Shivalik Rasayan Ecorecyling Tilaknagar Industries ULI IZMO

Main summary

Key takeaways

Finance

Finance/Markets Takeaways from the Video (Company Deep-Dives)

1) Shivalik Rasayan (agrochemicals) — value + turnaround thesis with heavy risks

Tickers/Companies/Instruments: Shivalik Rasayan Ltd; media biotech exposure (associated stake ~40%, “MedicaM Biotech” theme); promoter-linked references (“Bishnoi exports” mentioned); organophosphorus insecticides (e.g., dimethid, malion); regulatory context across the US/EU/China.

Key numbers & valuation metrics mentioned

  • Market cap: ~₹800 crore
  • Stock price: ~₹490 (described as near 52-week low, screenshot a few days old)
  • ROC: ~5.4%
  • PEG: -4
  • Profit trend (last ~3 years): negative; ~-13% CAR (as described)
  • P/E: ~54 (called “horrible” on screener)

Profitability / product / regulatory notes

  • Products: organophosphorus insecticides
  • Hazard notes:
    • Some described as Class 1 (most hazardous)
    • Others as Class 2 (slightly hazardous)
  • EU/US restrictions mentioned (e.g., “no approvals” for certain products in EU; US restricted), with continued registered/restricted usage elsewhere.

Working capital / capex signal

  • Capital work-in-progress (CWIP):
    • Mar 2024: ~₹57 (subtitle garbled; second figure appears as ~₹117)
    • Mar 2025: ~₹336 crore (capex included; described as rising)

Export contribution

  • Domestic revenue: ~99.92%
  • Exports: ~0.08%

Implied “logic path” / framework (not formal, but the reasoning is clear)

  • Start with: why look at a pessimistic stock despite weak ratios and losses.
  • Check regulatory/product cycle:
    • Hazardous products + restrictions (EU/US), but verify where approvals/registrations still exist.
  • Validate balance sheet & capex progress:
    • Rising CWIP/capex (Mar 2025 ~₹336 cr cited).
  • Review promoter-linked expansion plan:
    • Preferential capital raise + warrants (June 2023).
    • Transition from agrochemicals into pharma API + formulations via MedicaM Biotech (stake ~40%).
  • Identify operational triggers:
    • US/China progress (FDA/approvals/observations resolved, trial batches/facility approvals).
  • Build valuation on:
    • Improved capacity utilization
    • Turnaround in API losses → profits
    • A “two-year” horizon + multiple expansion

MedicaM Biotech theme — catalyst-style items

  • Preferential issue capital (June 2023): ~₹80 crore (majority described as from Danish entities; exact mechanics/rumors noted)
  • Transition toward new chemistry/non-organophosphorus categories (classes mentioned: “diamides / neonicotinoids”)
  • Pharma/API & R&D:
    • Mentions of niche therapeutic areas (type 2 diabetes, heart failure, CKD, oncology)—drug names garbled
    • US FDA API submission timeline: “applied” with patent until 2026 (one API name garbled: “C Lib”)
  • Milestones:
    • US FDA entity inspection: 7 observations (April 2024)
    • Haridwar facility approval: Oct 2024 (as stated)
  • Formulation approval note around 30 June 2025:
    • Vortex 3.5 mg injection
    • Rationale: premium/off-patent in India; expected higher cost in the US
  • Capacity utilization plan:
    • Range mentioned: ~15% → 35% (subtitle garbled)

Financial outcome logic (valuation target)

  • API/capex investment: ~₹112 crore (from “11,178” figure; units garbled but treated as ~₹112 cr)
  • “No further capex required” assumption (as presented)
  • Expected PAT (from API): ~₹56 crore
  • Expected combined PAT: ~₹75 crore total (agrochemicals + API; additional implied segments referenced)
  • Multiple application:
    • Current MCAP: ~₹800 cr
    • Target market cap: ~₹1,500 cr on ~20x P (FY27 mentioned)
    • Implied upside: ~100% in ~2 years
  • Technical overlay:
    • “Cup pattern” → expects ~100% move if it completes.

Explicit cautions / red flags mentioned

  • Long downward trend; possible “further lows”
  • Poor ROx, negative profit CAR, “horrible ratios”
  • Quarterly performance “not extraordinary”
  • Operating leverage not yet visible; losses attributed to depreciation + finance costs (new capex coming online)
  • Q&A notes:
    • Latest API division: revenue up, losses higher due to heavier depreciation + finance cost
  • Export dependence is tiny (0.08%), so early growth relies on approval-driven scaling.

2) Eco Recycling / E-waste recycling — growth theme with governance/disclosure risk

Tickers/Companies: “Eco Rico/Eco Recycling Limited” (BSE-listed) — other e-waste players mentioned with garbled names, but Eco Recycling is the core repeated name.

Key numbers & market/regulatory tailwinds

  • Sector growth: e-waste management expected ~12% CAGR till FY33 (timeline garbled)
  • Recycling economics (claims):
    • ~₹30 profit per kg of e-waste (con-call claim)
    • ~1 kg gold from 1 ton e-waste (asserted)
  • Industry split:
    • ~80% recycled informally vs ~20% formally → framed as ~4x opportunity
  • Capacity expansions (company-specific):
    • Total capacity: ~25,200 metric tons after adding 18,000 (timing garbled)
    • Added ~6,000 metric tons for lithium-ion battery recycling this year
  • Regulatory / tariff / EPR:
    • New CPCB/EPR rule: minimum payments ₹22/kg mentioned
    • Claimed price range: potential 5–15x current, with courts possibly reducing but not fully removing
    • Framed as major tailwind for formal recyclers

Major disclosure / governance risk (explicit emphasis)

  • Repeated concern about:
    • Annual reports delayed and fines for delay
      • FY24 published 19 Aug 24
      • FY23 also delayed
      • No annual report for FY25 yet
    • No recent calls (last con call ~Aug 2024)
    • Revenue mix not fully disclosed, especially:
      • EPR fees/credits vs actual recycling revenue
  • Investor concern: management may hold EPR credits but doesn’t clearly explain monetization, leading to concerns around inventory / receivables ballooning.

Financial metrics mentioned

  • Leverage: described as zero debt
  • ROE: improving to ~30%+ (numbers garbled but trend described: ~13% → 19% → 24% → 30%)
  • Share price referenced: ~₹600
  • Operating margin described as “good,” but questioned given EPR-credit holding and rising recycling expenses.

Key accounting / operational signals discussed

  • Inventory and trade receivables increasing sharply
    • Used to support the “EPR credit holding / deferred recognition” argument.

Valuation discussion

  • No explicit target multiple given, but implied:
    • Upside if disclosures improve and EPR credits get monetized
    • Downside if governance/disclosure issues persist

Explicit disclosure

  • One presenter disclosed holding: fractional percentage ~2.3% in portfolio.

3) Telknagar Industries Ltd (alcohol/spirits) — acquisition-driven shift from brandy to whiskey

Tickers/Companies: Tilaknagar Industries Limited (referred to as “Telknaga/Tilaknagar”)

Key numbers & corporate action

  • Background: started as Maharashtra sugar mills; acquisition-heavy distillery/sugar footprint in south India
  • Acquisition:
    • Imperial Blue (and “Imperial Black”) from Radico/Bernard Rico family context (subtitle garbled)
    • Deal value: ~₹4,150 crore
    • Claimed market reaction: portfolio expansion and stock price up ~25%
  • Volume:
    • 2024: Tilaknagar sold ~20 million cases
    • Imperial Blue sold ~22 million cases
  • Strategy: reduce brandy dominance; increase whiskey share

Transformation framework (step-by-step)

  • Product mix shift:
    • Current: ~95% brandy
    • Goal: reduce brandy to ~80%
    • Target: whiskey to ~67% share (stated repeatedly)
    • Plan ranges for brandy: ~30–37% (as described)
  • Geography shift:
    • Current dominance: ~85% of volume from South India
    • Target: diversify to North + East
    • Reduce South to ~50%, aiming for Pan-India 50/50

Financial metrics mentioned

  • Profitability:
    • PAT margin / OPM around ~17%–18% (OPM referenced ~20% at one point)
    • ROE around ~30%
  • Growth:
    • From FY22 to FY25: profits and EPS growth mentioned
    • EPS: ~4.1 → 14.3 (as stated)
  • (Some revenue growth figures garbled)

Valuation / technical view

  • Stock price referenced: ~₹490
  • Technical pattern:
    • Cup/handle; target zone:
      • ~₹700+
      • Suggested ~25–30% upside if pattern completes
  • Macro risk mentioned:
    • US tariff on wines/spirits referenced as ~112%, but concluded direct US export impact is limited.
  • State policy/tax risk:
    • Example given: Karnataka tax up to ~86%
    • Alcohol not allowed in certain states

4) IZMO (automotive software/AI + CGI/VR + semicon packaging bet) — high-risk micro/small-cap “futurist” thesis

Tickers/Companies: IZMO Divisions/themes: ISMO Cars, ISMO Studio, Frog Data AI, and a subsidiary/theme: ISMO Micro (semiconductor packaging).

Explicit disclaimer (risk)

  • Presenter: not SEBI-registered
  • Not advice to buy/sell
  • Warns the stock “could turn zero” long-term.

Business model & theme

  • SaaS/digital retail + AI decision analytics for automotive dealers
  • Uses CGI/VR image libraries:
    • Client churn claim: ~2%
  • Frog Data AI:
    • Dealer pricing/inventory/vehicle demand analytics to boost margins
  • ISMO Micro + semiconductors packaging:
    • “System-in-package” and silicon photonics packaging
    • Collaboration with IIT Madras
    • Claims: high density silicon photonics (32-channel I/O; insertion loss < 2 dB)
    • Mentions:
      • “fiber array”
      • silicon photonics QRNG (quantum random number generator)
      • supply to DRD for advanced quantum cryptography (as stated)

AI/market opportunity numbers mentioned

  • Digital marketing SaaS growth: ~11.3% CAGR to ~$800B by 2028 (as stated)
  • AI market: ~$1.8T by 2030 with ~36% CAGR
  • Dealer economics (US-focused):
    • ~75 million unit sales in 2023
    • ~20,000 dealers
    • Dealer marketing spend: ~$60,000/month
    • Claimed adoption cost: ~$3,500 (~5% of spend)

Revenue/earnings targets & valuation

  • Company-provided targets:
    • ISMO Micro: ~₹200 crore topline in ~3–4 years with ~60–70% gross margins
  • Frog Data / overall projections (as stated):
    • Sales: ~₹500 cr (3.5–4 years scenario)
    • PAT: ~₹110 cr
    • Implied market cap target: ~₹3,650 cr (using assumed multiple/rerating)
  • Bear-case:
    • If execution falters → multiple compression → stock could drop meaningfully.

Risks called out explicitly

  • Data security/cyber risk:
    • Repository security; customer loss if hacked or images manipulated
  • Talent retention in AI
  • Currency fluctuation impact (North America/Europe focus)
  • Contingent liabilities from income tax department not provisioned
  • Low promoter stake (~28% stated) and “skin in the game” concern

5) RBI/Uli (Uniform Lending Interface) — macro fintech theme, investment-sector implications

Tickers/Companies (mentioned broadly): RBI; NPCI/UPI; several infrastructure/tech names garbled; examples include Persistent Systems, potential Cyient/Tech Mahindra, Subex (unclear), Mindtree (unclear).

Macro framework

  • Clarified: not a stock, but a policy/fintech “digital public infrastructure” presentation.

Core methodology described (credit access mechanism)

  • Use ULI (Uniform Lending Interface) as a standardized layer between banks and borrowers
  • Borrower identification via Aadhaar
  • System fetches verified records:
    • State government property records
    • MSME records
    • Startup registration records
  • Automated valuation estimate from verified data
  • Bank issues loans with interest rate constrained by transparency in process

Timeline

  • Pilot: already completed / some banks onboarded (example mentioned: PNB)
  • Full rollout targeted by 2026–2027
  • GDP uplift estimate: +0.5% (as stated)

Investment implications suggested

  • Direct beneficiaries:
    • Rural-focused banks (simpler underwriting)
    • Payment aggregators/rails (examples: Paytm, PhonePe; plus aggregators like Razorpay/PayU—names partly garbled)
    • Data centers (more data)
    • AI/fraud detection systems (lower NPA through better verification)
  • Indirect beneficiaries:
    • Agri / agribusiness and agri-tech startups (if credit expands)

Disclosures / Disclaimers Noted

  • IZMO presentation: “Not SEBI-registered advisor; not advice to buy/sell; invest responsibly; may become zero.”
  • Eco Recycling: portfolio exposure disclosed at ~2.3% (fractional).
  • Other presenters: generally framed as research/thesis discussion; IZMO was the explicit “not advice” disclosure.

Presenters / Sources Mentioned (as identifiable in the transcript)

  • Mu — presenter of the Shivalik Rasayan / MedicaM Biotech thesis (first segment)
  • Sumit — Eco Recycling / e-waste investing discussion
  • Rashmi Patel / Rashmi G. — Tilaknagar Industries presentation
  • Ranji — ULI / Uniform Lending Interface policy + investment theme
  • (Unspecified presenter of last slot) — IZMO automotive software + semicon packaging thesis (name not clearly captured)
  • Punit — host/moderator referenced repeatedly (session management/timing)

(Some names and ticker formats are partially garbled due to subtitle auto-generation.)

Rate this summary

Your feedback will help improve summaries.

Improve this summary

Reprocess with a stronger model when the summary feels incomplete or inaccurate.

Pro

Translate summary in another language

Pro

Ask questions to this video

Chat for follow-up questions, clarifications, and source-backed answers.

Coming soon

Share this summary

Share on X/Twitter Share on LinkedIn Share on Reddit

Original video